Quick Answer
Processa Pharmaceuticals, Inc. reported Total Revenue of $5.0 thousand for fiscal year 2016.
Processa Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$13.56M -14.5% |
-$11.85M -6.6% |
-$11.12M +59.4% |
-$27.42M -140.0% |
-$11.43M +20.7% |
-$14.41M -329.3% |
| Diluted EPS | -$10.36 +89.3% |
-$96.78 -1041.3% |
-$8.48 +75.1% |
-$34.05 | — | — |
| Total Assets | $7.81M +142.0% |
$3.23M -44.2% |
$5.79M -32.9% |
$8.62M -67.4% |
$26.46M +5.0% |
$25.21M +131.7% |
| Cash and Equivalents | $5.54M +364.8% |
$1.19M -74.7% |
$4.71M -27.6% |
$6.50M -60.6% |
$16.50M +7.0% |
$15.42M +2129.3% |
| Stockholders Equity | $5.58M +228.8% |
$1.70M -66.0% |
$4.99M -33.2% |
$7.47M -70.7% |
$25.49M +11.1% |
$22.94M +186.3% |
| R&D Expense | — | — | — | — | — | $3.17M +36.7% |
| Operating Income | -$13.99M -16.1% |
-$12.05M -5.2% |
-$11.46M +58.4% |
-$27.53M -126.9% |
-$12.13M +19.8% |
-$15.14M -284.6% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 2.57M +100.0% |
1.29M +0.0% |
1.29M +60.4% |
801,774 -94.9% |
15.71M +10.8% |
14.18M +158.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2016 | $5.0K | -86.8% | -91.4% |
| Net Income | September 30, 2025 | -$3.44M | -1.5% | +12.6% |
| Diluted EPS | September 30, 2025 | -$0.07 | +93.2% | +72.0% |
| Total Assets | September 30, 2025 | $7.58M | +53.5% | -7.3% |
| Cash and Equivalents | September 30, 2025 | $6.31M | +118.2% | -9.1% |
| Stockholders Equity | September 30, 2025 | $5.83M | +56.8% | -4.5% |
| R&D Expense | March 31, 2022 | $2.04M | +38.5% | +38.5% |
| Operating Income | September 30, 2025 | -$3.49M | -1.9% | +11.7% |
| Gross Profit | March 31, 2016 | $5.0K | -60.9% | -67.8% |
| Shares Outstanding | September 30, 2025 | 52.86M | +1518.1% | +31.2% |
- Processa Pharmaceuticals, Inc. reported Total Revenue of $5.0 thousand for fiscal year 2016.
- Processa Pharmaceuticals, Inc. showed a decrease of -95.6% in Total Revenue compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported Net Income of -$13.56 million for fiscal year 2025.
- Processa Pharmaceuticals, Inc. showed a decrease of -14.5% in Net Income compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported Diluted EPS of $10.36 per share (loss) for fiscal year 2025.
- Processa Pharmaceuticals, Inc. showed an increase of +89.3% in Diluted EPS compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported Total Assets of $7.81 million for fiscal year 2025.
- Processa Pharmaceuticals, Inc. showed an increase of +142.0% in Total Assets compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported Cash and Equivalents of $5.54 million for fiscal year 2025.
- Processa Pharmaceuticals, Inc. showed an increase of +364.8% in Cash and Equivalents compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported Stockholders Equity of $5.58 million for fiscal year 2025.
- Processa Pharmaceuticals, Inc. showed an increase of +228.8% in Stockholders Equity compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported R&D Expense of $3.17 million for fiscal year 2020.
- Processa Pharmaceuticals, Inc. showed an increase of +36.7% in R&D Expense compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported Operating Income of -$13.99 million for fiscal year 2025.
- Processa Pharmaceuticals, Inc. showed a decrease of -16.1% in Operating Income compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported Gross Profit of $5.0 thousand for fiscal year 2016.
- Processa Pharmaceuticals, Inc. showed an increase of +140.2% in Gross Profit compared to the prior fiscal year.
- Processa Pharmaceuticals, Inc. reported Shares Outstanding of 2.57 million shares for fiscal year 2025.
- Processa Pharmaceuticals, Inc. showed an increase of +1636.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: